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Background
PD-L1 regulates CD8 T cell/Th1 immune responses.
PD-L1 expressed in the tumor microenvironment can
bind to PD-1 or B7.1 on activated T cells and mediate
cancer immune evasion. MPDL3280A is a human mAb
containing an engineered Fc-domain designed to opti-
mize efficacy and safety that targets PD-L1 and blocks it
from binding to its receptors.
Methods
Immunologic pharmacodynamics effects were evaluated
in tumors and bloods from patients treated with
MPDL3280A. MPDL3280A was administered IV q3w in
>300 pts with locally advanced or metastatic solid
tumors. PD-L1 and CD8 were measured by IHC. PD-L1
expression was evaluated in tumor and intra-tumoral
immune cells. CD8 was assessed in the tumor center,
periphery and invasive margin. The expression of ≈90
immune-related markers was evaluated at baseline (BL)
and on-treatment using a custom-designed immunochip.
BL tumor samples were available for 125 pts, and
matched on-treatment samples were available for 31 pts.
Further, blood-based biomarkers and circulating immune
subsets were serially measured in 114 patients by modi-
fied ELISA and FACS, respectively.
Results
On treatment, responding tumors showed increase in
expression of tumor cell PD-L1 and infiltration of CD8+
T-cells and a Th1-dominant immune infiltrate, providing
evidence for adaptive PD-L1 up-regulation. Non-responders
showed minimal tumor CD8+ T-cell infiltration and an
absence of T-cell activation (measured by Granzymes,
Perforin and EOMES expression). We also profiled circulat-
ing biomarkers for their association with clinical outcomes.
A sub-population of patients, including those with RCC and
melanoma, exhibited elevated PD-L1 expression on circulat-
ing T-cells at BL that was associated with response to
MPDL3280A. On treatment, we observed a delayed increase
in frequency of CD4+ICOS+ and CD4+PD1+ T-cells in
patients responding to MPDL3280A monotherapy. In con-
trast, frequency of CD8+HLA-DR+Ki67+ T-cells increased
shortly following the first dose of MPDL3280A and
returned to baseline levels by the end of cycle 2 when
assessed in all patients, representing a transient pharmaco-
dynamic measurement of PD-L1 inhibition. On-treatment,
increase in plasma IL-6 was associated with disease progres-
sion. Associations with other circulating markers of inflam-
mation including CRP with clinical outcomes will be
presented.
Conclusions
Our data show that changes in pharmacodynamic
immune markers are associated with clinical outcomes to
MPDL3280A. These data provide mechanistic insights
into immune checkpoint inhibition in cancer and identify
potential biomarkers that may be monitored as on-treat-
ment markers of clinical activity for patients treated with
inhibitors of PD-L1/PD1 pathway.
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